Reply to Wolowich and Kwon.

Zhang, Miao; Yao, Xueting; Cui, Cheng; Liu, Xu; Li, Haiyan; Liu, Dongyang

Zhang, Miao; Yao, Xueting; Cui, Cheng; Liu, Xu; Li, Haiyan; Liu, Dongyang.

Zhang M; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Yao X; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Cui C; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Liu X; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Li H; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Liu D; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.

Clin Infect Dis ; 72(9): 1678-1680, 2021 05 04.

Article in English | MEDLINE | ID: covidwho-1223326

Subject(s)

COVID-19 Drug Treatment; SARS-CoV-2; Antiviral Agents; Humans; Hydroxychloroquine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google